Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u26054","jir_publication_date":"2025-12-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2025\/12\/4507-20251222-04.pdf","jir_short_summary":"Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.","jir_summary":"### Overview of the Transaction\nShionogi & Co., Ltd. resolved at its Board of Directors meeting on December 22, 2025, to conclude an agreement to acquire all global rights, including intellectual property and sales rights, for Edaravone, a treatment for amyotrophic lateral sclerosis (ALS) and other conditions developed and marketed by Tanabe Pharma Corporation (product name in Japan: Radicut, product name in the US: Radicava). The transaction amount is 2.5 billion USD (approximately 394,175 million JPY). In the US, Shionogi Inc. will make the newly established Radicava business company a wholly owned subsidiary. The complete subsidiary acquisition of the Radicava business company is expected to occur after April 1, 2026, and the business is anticipated to contribute to revenue and profits from the fiscal year ending March 2027.\n\n### Purpose and Background of the Transaction\nThis acquisition is part of Shionogi\u2019s strategy to realize one of its material issues, \"Contributing to a Healthy and Enriched Life,\" by focusing on quality-of-life (QOL) diseases with high social impact, such as sleep disorders, hearing loss, and rare diseases. By acquiring full rights to Edaravone, an innovative treatment for the rare disease ALS that meets significant unmet medical needs, and incorporating personnel and business operation expertise experienced in rare disease domains, Shionogi aims to establish a strong sales foundation in the US market and accelerate the development and provision of rare disease therapies.","jir_financial_highlights":"Transaction Amount: 2,500 million USD (amount converted to JPY: 394,175 million JPY) (Unknown)","jir_category":"M&A\/Alliance, Strategy\/Investment","jir_hashtags":"#ShionogiCoLtd, #M&A, #JapaneseStocks","jir_key_figures":"Transaction Type: Business Acquisition\nTarget Company: Tanabe Pharma Corporation\nTransaction Amount: 2,500 million USD (approximately 394,175 million JPY)\nExpected Completion Date: From April 2026 onward\nExpected Synergies: Contribution to revenue and profits from fiscal year ending March 2027","jir_meta_title":"Shionogi Acquires Tanabe Pharma\u2019s Edaravone Business to Strengthen Global Expansion","jir_meta_description":"Shionogi acquires the Edaravone business for amyotrophic lateral sclerosis from Tanabe Pharma for 2.5 billion USD. From April 2026, the US business company will become a wholly owned subsidiary, enhancing its rare disease business foundation.","jir_og_title":"Shionogi Announces Acquisition of Tanabe Pharma\u2019s Edaravone Business","jir_og_description":"Shionogi acquires global rights to Tanabe Pharma\u2019s ALS treatment Edaravone business, expected to contribute to revenue and profits from fiscal year ending March 2027.","jir_og_image_url":"\/assets\/og\/company-m-a-alliance.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-8294","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n